



[Go to Product page](#)

Datasheet for ABIN7200668

## Recombinant anti-PDCD1 (Pembrolizumab Biosimilar) antibody

### Overview

|                |   |
|----------------|---|
| Quantity:      | 1 mg  |
| Target:        | PDCD1 (Pembrolizumab Biosimilar)                                |
| Reactivity:    | Human   |
| Host:          | Mouse   |
| Antibody Type: | Recombinant Antibody  |
| Clonality:     | Monoclonal  |
| Conjugate:     | This PDCD1 (Pembrolizumab Biosimilar) antibody is un-conjugated |
| Application:   | In vivo Studies (in vivo), Flow Cytometry (FACS)                |

### Product Details

|                  |   |
|------------------|---|
| Purpose:         | Pembrolizumab Biosimilar, Human PD-1 Monoclonal Antibody  |
| Immunogen:       | The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody pembrolizumab biosimilar was produced in the pembrolizumab biosimilar CHO stable cell line.                                     |
| Isotype:         | IgG4 kappa  |
| Specificity:     | The in vivo grade pembrolizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1 or PD1), antagonizing its interaction with its known ligands PD-L1 or PDL1, and PD-L2 or PDL2. |
| Characteristics: | Recombinant Humanized IgG4 Monoclonal Antibody.   |
| Purification:    | Protein A affinity column   |
| Purity:          | > 95% by SDS-PAGE under reducing conditions and HPLC.   |

## Product Details

---

|                  |   |
|------------------|---|
| Sterility:       | 0.2 µm filtered                                   |
| Endotoxin Level: | < 1 EU per 1 mg of the protein by the LAL method. |

## Target Details

---

|              |  |
|--------------|--|
| Target:      | PDCD1 (Pembrolizumab Biosimilar)   |
| Abstract:    | <a href="#">PDCD1 (Pembrolizumab Biosimilar) Products</a>  |
| Target Type: | Biosimilar   |
| Background:  | What is Pembrolizumab biosimilar research grade? Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. Pembrolizumab Biosimilar uses the same protein sequences as the therapeutic antibody pembrolizumab. |

## Application Details

---

|                    |  |
|--------------------|--|
| Application Notes: | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pembrolizumab. |
| Restrictions:      | For Research Use only  |

## Handling

---

|                  |   |
|------------------|---|
| Format:          | Liquid  |
| Concentration:   | 1 mg/mL   |
| Buffer:          | PBS, pH 7.4, no stabilizers or preservatives.   |
| Preservative:    | Without preservative  |
| Handling Advice: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.   |
| Storage:         | -20 °C  |
| Storage Comment: | 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Expiry Date:     | 12 months   |